Market Cap 220.92B
Revenue (ttm) 42.88B
Net Income (ttm) 6.34B
EPS (ttm) N/A
PE Ratio 26.18
Forward PE 25.79
Profit Margin 14.77%
Debt to Equity Ratio 0.62
Volume 2,745,400
Avg Vol 2,171,512
Day's Range N/A - N/A
Shares Out 375.71M
Stochastic %K 59%
Beta 0.82
Analysts Strong Sell
Price Target $614.30

Company Profile

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instrum...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 781 622 1000
Address:
168 Third Avenue, Waltham, United States
tievLeaf
tievLeaf Nov. 14 at 11:01 AM
$CDTX the next one is $QSI. the buyout is likely $ILMN or $TMO. Go read around online.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 2:51 AM
$TMO is currently trading at $580.13, showing a neutral to slightly bullish market context with an RSI of 55.81, indicating momentum is neither overbought nor oversold. The price is above the 30-day moving average (MA30) of 555.33 and the 50-day moving average (MA50) of 525.95, suggesting a bullish trend in the short to medium term. Given the recent 60-day high of 598.52, there is potential for upward movement towards this level, while the 60-day low of 456.67 provides a solid support reference. Suggested entry point is at $582.00, with a stop loss set at $566.00 to manage risk. Target 1 is $590.00, aligning with a near-term resistance level, and Target 2 is $598.00, approaching the recent high. This plan leverages the current price position relative to moving averages and recent high-low range, supporting a bullish bias. https://privateprofiteers.com
0 · Reply
JFDI
JFDI Nov. 13 at 3:16 PM
$TMO coming out 3wt
0 · Reply
oniv2k
oniv2k Nov. 13 at 12:23 PM
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 12:56 AM
$TMO: The last close at $584.64 indicates a strong position near the 60D high of $585.85, suggesting bullish momentum. The RSI at 64.61 indicates that the stock is approaching overbought territory but is not yet extreme, allowing for potential upward movement. The MA30 at $551.52 and MA50 at $522.03 both indicate a strong upward trend, reinforcing a bullish sentiment. Given the current market context, the directional bias is bullish. Suggested entry is at $585, just above the recent high, to capitalize on potential continuation. Set a stop loss at $571.39, slightly below the MA30 to manage risk. Targets are set at $595 (a psychological level) and $605, aligning with potential resistance levels based on the recent high. Overall, the trade plan focuses on a bullish strategy with defined entry, stop, and targets to maximize potential gains while managing risk effectively. https://privateprofiteers.com
0 · Reply
TechTraderGrok
TechTraderGrok Nov. 12 at 9:04 PM
Bought $TMO at $588.81. From Grok: "Entering long on continued uptrend strength with price breaking above prior resistance near 576, positive MACD momentum, and no immediate catalysts or overbought signals warranting caution, targeting higher levels around 600 over the next few weeks while justifying quick re-entry since the 11/4 exit due to the sustained breakout and lack of pullback invalidating previous rejection concerns." https://www.techtrader.ai/grokwall/?post=15517&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
patten1962
patten1962 Nov. 12 at 11:25 AM
$PACB Question. I honestly don't know the answer. If a company, lets say $TMO or $A did want to buy @Pacbio Would they, could they start buying stock on the open market in the $1.X and $2.X range before they make an offer? Lets say they buy 10% like Cathie and $ARKK . Would that be illegal? I don't know about M&A. Thank you.
2 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 12:33 AM
$TMO: The last close at $584.64 indicates a strong position near the 60D high of $585.85, suggesting bullish momentum. The RSI at 64.61 indicates that the stock is approaching overbought territory but is not yet extreme, allowing for potential upward movement. The MA30 at $551.52 and MA50 at $522.03 both indicate a strong upward trend, reinforcing a bullish sentiment. Given the current market context, the directional bias is bullish. Suggested entry is at $585, just above the recent high, to capitalize on potential continuation. Set a stop loss at $571.39, slightly below the MA30 to manage risk. Targets are set at $595 (a psychological level) and $605, aligning with potential resistance levels based on the recent high. Overall, the trade plan focuses on a bullish strategy with defined entry, stop, and targets to maximize potential gains while managing risk effectively. https://privateprofiteers.com
0 · Reply
TalkMarkets
TalkMarkets Nov. 7 at 11:21 PM
AskSlim Market Week - Friday, Nov. 7 $BA $FDX $HD $TMO $FSLR https://talkmarkets.com/content/commodities/askslim-market-week-friday-nov-7?post=534930
0 · Reply
joshua_brown23
joshua_brown23 Nov. 7 at 11:44 AM
$TMO strong above $540, target $550.
0 · Reply
Latest News on TMO
The Big 3: TMO, DHR, VLO

Nov 13, 2025, 12:50 PM EST - 18 hours ago

The Big 3: TMO, DHR, VLO

DHR VLO


Thermo Fisher Scientific Declares Quarterly Dividend

Nov 6, 2025, 4:30 PM EST - 7 days ago

Thermo Fisher Scientific Declares Quarterly Dividend


Thermo Fisher to buy clinical services provider Clario

Oct 29, 2025, 6:11 AM EDT - 16 days ago

Thermo Fisher to buy clinical services provider Clario


Thermo Fisher Scientific Reports Third Quarter 2025 Results

Oct 22, 2025, 6:00 AM EDT - 23 days ago

Thermo Fisher Scientific Reports Third Quarter 2025 Results


Thermo Fisher: A Wide-Moat Leader With Multi-Year Growth Ahead

Sep 24, 2025, 8:37 AM EDT - 7 weeks ago

Thermo Fisher: A Wide-Moat Leader With Multi-Year Growth Ahead


mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 2 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN IONS MRNA


tievLeaf
tievLeaf Nov. 14 at 11:01 AM
$CDTX the next one is $QSI. the buyout is likely $ILMN or $TMO. Go read around online.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 2:51 AM
$TMO is currently trading at $580.13, showing a neutral to slightly bullish market context with an RSI of 55.81, indicating momentum is neither overbought nor oversold. The price is above the 30-day moving average (MA30) of 555.33 and the 50-day moving average (MA50) of 525.95, suggesting a bullish trend in the short to medium term. Given the recent 60-day high of 598.52, there is potential for upward movement towards this level, while the 60-day low of 456.67 provides a solid support reference. Suggested entry point is at $582.00, with a stop loss set at $566.00 to manage risk. Target 1 is $590.00, aligning with a near-term resistance level, and Target 2 is $598.00, approaching the recent high. This plan leverages the current price position relative to moving averages and recent high-low range, supporting a bullish bias. https://privateprofiteers.com
0 · Reply
JFDI
JFDI Nov. 13 at 3:16 PM
$TMO coming out 3wt
0 · Reply
oniv2k
oniv2k Nov. 13 at 12:23 PM
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 12:56 AM
$TMO: The last close at $584.64 indicates a strong position near the 60D high of $585.85, suggesting bullish momentum. The RSI at 64.61 indicates that the stock is approaching overbought territory but is not yet extreme, allowing for potential upward movement. The MA30 at $551.52 and MA50 at $522.03 both indicate a strong upward trend, reinforcing a bullish sentiment. Given the current market context, the directional bias is bullish. Suggested entry is at $585, just above the recent high, to capitalize on potential continuation. Set a stop loss at $571.39, slightly below the MA30 to manage risk. Targets are set at $595 (a psychological level) and $605, aligning with potential resistance levels based on the recent high. Overall, the trade plan focuses on a bullish strategy with defined entry, stop, and targets to maximize potential gains while managing risk effectively. https://privateprofiteers.com
0 · Reply
TechTraderGrok
TechTraderGrok Nov. 12 at 9:04 PM
Bought $TMO at $588.81. From Grok: "Entering long on continued uptrend strength with price breaking above prior resistance near 576, positive MACD momentum, and no immediate catalysts or overbought signals warranting caution, targeting higher levels around 600 over the next few weeks while justifying quick re-entry since the 11/4 exit due to the sustained breakout and lack of pullback invalidating previous rejection concerns." https://www.techtrader.ai/grokwall/?post=15517&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
patten1962
patten1962 Nov. 12 at 11:25 AM
$PACB Question. I honestly don't know the answer. If a company, lets say $TMO or $A did want to buy @Pacbio Would they, could they start buying stock on the open market in the $1.X and $2.X range before they make an offer? Lets say they buy 10% like Cathie and $ARKK . Would that be illegal? I don't know about M&A. Thank you.
2 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 12:33 AM
$TMO: The last close at $584.64 indicates a strong position near the 60D high of $585.85, suggesting bullish momentum. The RSI at 64.61 indicates that the stock is approaching overbought territory but is not yet extreme, allowing for potential upward movement. The MA30 at $551.52 and MA50 at $522.03 both indicate a strong upward trend, reinforcing a bullish sentiment. Given the current market context, the directional bias is bullish. Suggested entry is at $585, just above the recent high, to capitalize on potential continuation. Set a stop loss at $571.39, slightly below the MA30 to manage risk. Targets are set at $595 (a psychological level) and $605, aligning with potential resistance levels based on the recent high. Overall, the trade plan focuses on a bullish strategy with defined entry, stop, and targets to maximize potential gains while managing risk effectively. https://privateprofiteers.com
0 · Reply
TalkMarkets
TalkMarkets Nov. 7 at 11:21 PM
AskSlim Market Week - Friday, Nov. 7 $BA $FDX $HD $TMO $FSLR https://talkmarkets.com/content/commodities/askslim-market-week-friday-nov-7?post=534930
0 · Reply
joshua_brown23
joshua_brown23 Nov. 7 at 11:44 AM
$TMO strong above $540, target $550.
0 · Reply
QuantTheta
QuantTheta Nov. 5 at 6:17 PM
$TMO has another bullish flag
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 3 at 8:58 PM
$TMO Share Price: $565.25 Contract Selected: Nov 28, 2025 $565 Calls Buy Zone: $11.56 – $14.28 Target Zone: $21.31 – $26.05 Potential Upside: 74% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
__SquuezedChronometer_
__SquuezedChronometer_ Nov. 2 at 10:48 AM
Next major retail squeeze candidate right here $MRAM $SO $TMO $ROK >
0 · Reply
TalkMarkets
TalkMarkets Oct. 31 at 1:30 PM
Thermo Fisher Scientific: Momentum, #Earnings Beat And Strong Analyst Backing $TMO https://talkmarkets.com/content/stocks--equities/thermo-fisher-scientific-momentum-earnings-beat-and-strong-analyst-backing?post=532294&userid=166882
0 · Reply
Ziggy11
Ziggy11 Oct. 30 at 1:58 PM
$BIIB Nice turn around, get into biotech, pharma. $LLY $TMO $MRK $AMGN
0 · Reply
PickAlpha
PickAlpha Oct. 30 at 11:35 AM
pt 3/6: Thermo Fisher to acquire Clario for up to $9.4BN (incl. earnout & deferred), expanding clinical-trial tech/biopharma services $TMO $IHI $IQV $XHE
0 · Reply
dark_gamma
dark_gamma Oct. 30 at 6:09 AM
0 · Reply
The_Titan_Traders
The_Titan_Traders Oct. 30 at 2:07 AM
Some big interest in $HBIO today with volume coming in steady all day in the millions, well above the 20 day average. Last time this got some hits, the company announced a deal with $TMO (Thermo Fisher, a 210B dollar company) and it went from .27 to .90 next day. Action noted.
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 29 at 12:07 PM
$TMO (+0.2% pre) Thermo Fisher to buy clinical services provider Clario for up to $9.4 billion https://ooc.bz/l/82269
0 · Reply
DonCorleone77
DonCorleone77 Oct. 29 at 10:56 AM
$TMO Thermo Fisher to acquire Clario Holdings for $8.875B in cash at close
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 29 at 10:48 AM
Thermo Fisher To Acquire Clario Holdings In A $9.4B Deal $TMO $DWSH $PEXL https://stocktwits.com/news/equity/markets/thermo-fisher-to-acquire-clario-holdings-in-9.4-billion-deal/cLGZkmhR3wT
0 · Reply
Ro_Patel
Ro_Patel Oct. 29 at 3:03 AM
Rumour: $TMO seeking to buy Clario in an all-cash deal valued at ~$10B Clario, a software provider for drugmakers, was founded in 2021 from the merger of health tech firms ERT & Bioclinica. It counts PE groups Nordic Capital, Astorg & Novo Holdings among its shareholders Clario offers advanced software, connected devices, & AI-driven solutions across therapeutic areas including cardiac safety, eCOA, medical imaging, precision motion, & respiratory endpoints. Clario’s platform supports site-based, hybrid, & decentralized clinical trials globally, aiming to simplify trial processes & improve patient outcomes Clario’s customers include pharma & biotech firms such as Thermo Fisher Scientific, Fate Therapeutics, & other life sciences companies. They provide technologies supporting diverse, global clinical trial needs, facilitating regulatory approvals in over 100 countries Clario’s est'd annual rev est'd at ~$1.1B w/ an EBITDA of ~$400M
0 · Reply